Form 4: Akero Therapeutics COO Jonathan Young Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 5,000 shares of common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 1, 2024, Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 5,000 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan established on December 27, 2023.
• The shares were sold at a weighted-average price of $20.1499, with individual transactions ranging from $19.715 to $20.58.
• Following the transaction, Young directly owns 258,306 shares.
• Young also has indirect ownership of 60,000 shares held in irrevocable trusts for his children, for which he disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it simply reports a stock sale under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan helps to alleviate these concerns.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, depending on how the market interprets the transaction.

Key Dates